<SEC-DOCUMENT>0001171843-12-004518.txt : 20121217
<SEC-HEADER>0001171843-12-004518.hdr.sgml : 20121217
<ACCEPTANCE-DATETIME>20121217170016
ACCESSION NUMBER:		0001171843-12-004518
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20121212
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20121217
DATE AS OF CHANGE:		20121217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XOMA Corp
		CENTRAL INDEX KEY:			0000791908
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942756657
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14710
		FILM NUMBER:		121269197

	BUSINESS ADDRESS:	
		STREET 1:		2910 SEVENTH ST
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5106441170

	MAIL ADDRESS:	
		STREET 1:		2910 SEVENTH ST
		CITY:			BERKLEY
		STATE:			CA
		ZIP:			94710

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA LTD /DE/
		DATE OF NAME CHANGE:	19990107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA CORP /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>document.htm
<DESCRIPTION>FORM 8-K FILING DOCUMENT
<TEXT>
<html>

	<head>
		<title>Form 8-K Filing</title>
	</head>

	<body>
		<p align="center"><b>UNITED STATES</b><br>
			<b>SECURITIES AND EXCHANGE COMMISSION</b><br>
			<b>Washington, D.C. 20549</b><br>
		</p>
		<p align="center"><b>FORM 8-K</b></p>
		<p align="center"><font size="2"><b>CURRENT REPORT</b><br>
					Pursuant to Section 13 or 15(d) of the<br>
					Securities Exchange Act of 1934</font></p>
		<p align="center"><font size="2">Date of Report (Date of earliest event Reported): December 12, 2012</font></p>
		<p align="center"><font size="5">XOMA CORPORATION</font><br>
			<font size="2">(Exact Name of Registrant as Specified in Charter)</font></p>
		<p align="center"><!-- Registrant's State of Inc, File and IRS Number --><font size="2">DELAWARE</font><br>
			<font size="2">(State or Other Jurisdiction of Incorporation)</font></p>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="50%" align="center"><font size="2">000-14710</font></td>
				<td width="50%" align="center"><font size="2">52-2154066</font></td>
			</tr>
			<tr valign="top">
				<td width="50%" align="center"><font size="2">(Commission File Number) </font></td>
				<td width="50%" align="center"><font size="2">(I.R.S. Employer Identification Number) </font></td>
			</tr>
		</table>
		<!-- Registrant's Postal Addess and Zip Code --><br>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="bottom">
				<td width="47%" align="center"><font size="2">2910 Seventh Street, Berkeley, California</font></td>
				<td width="47%" align="center"><font size="2">94710</font></td>
			</tr>
			<tr valign="top">
				<td width="47%" align="center"><font size="2">(Address of Principal Executive Offices) </font></td>
				<td width="47%" align="center"><font size="2">(Zip Code)</font></td>
			</tr>
		</table>
		<p align="center"><font size="2">Registrant's telephone number, including area code: (510) 204-7200</font></p>
		<p align="center"><br>
			<font size="2">Not applicable<br>
			(Former name or former address, if changed since last report)</font></p>
		<!-- Simultaneous filing obligation checkboxes --><br>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td colspan="3"><font size="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
						<br>
					</font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></td>
			</tr>
		</table>
		<br>
		<hr noshade="1">
		<font size="2"></font>
		<p><b><p><font size="3"><b>Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></font></p></b></p>
		<p><font size="2"><p>
	(d) On December 12, 2012, the Board of Directors of XOMA Corporation (the &quot;Company&quot;) appointed Joseph M. Limber to serve as a member of the Company&#39;s Board of Directors. With the appointment of Mr. Limber, the Company&#39;s Board of Directors consists of consists of nine directors.</p>
<p>
	 </p>
<p>
	A copy of the Company&#39;s press release relating to Mr. Limber&#39;s appointment as director is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Exhibit 99.1 shall not be deemed &quot;filed&quot; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &quot;Exchange Act&quot;), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Exchange Act.</p>
</font></p>
		<font size="2"></font>
		<p><b><p><font size="3"><b>Item 9.01. Financial Statements and Exhibits.</b></font></p></b></p>
		<p><font size="2"><p>
	<b>(d) Exhibits</b></p>
<p>
	The following exhibit is furnished as part of this Current Report on Form 8-K:</p>
<table border="0" cellpadding="0" cellspacing="0">

		<tr>
			<td>
				<font size="2"><b><u>Exhibit Number</u></b></font></td>
			<td rowspan="3" width="15">
				 </td>
			<td>
				<font size="2"><b><u>Description</u></b></font></td>
		</tr>
		<tr>
			<td>
				 </td>
			<td>
				 </td>
		</tr>
		<tr>
			<td>
				<font size="2">99.1</font></td>
			<td>
				<font size="2">Press Release, dated December 13, 2012.</font></td>
		</tr>

</table>
</font></p>
		<hr noshade="1">
		<!-- Registrant's Signature -->
		<p align="center"><b><font size="2">SIGNATURE</font></b></p>
		<p><font size="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="47%" valign="top"><font size="2">Dated: December 17, 2012</font></td>
				<td colspan="2" valign="top"><font size="2">XOMA CORPORATION<br>
					<br>
					</font></td>
			</tr>
			<tr valign="top">
				<td width="47%">
					<p></p>
				</td>
				<td width="5%"><font size="2">&nbsp;By: &nbsp;</font></td>
				<td width="47%"><font size="2"><u>/s/ FRED KURLAND</u><br>
					Fred Kurland<br>
					Vice President, Finance and<br>Chief Financial Officer</font></td>
			</tr>
		</table>
		<font size="2"><hr />
<p>
	 </p>
<p align="center">
	<b>EXHIBIT INDEX</b></p>
<p>
	 </p>
<table border="0" cellpadding="0" cellspacing="0">

		<tr>
			<td>
				<font size="2"><b><u>Exhibit Number</u></b></font></td>
			<td rowspan="3" width="15">
				 </td>
			<td>
				<font size="2"><b><u>Description</u></b></font></td>
		</tr>
		<tr>
			<td>
				 </td>
			<td>
				 </td>
		</tr>
		<tr>
			<td>
				<font size="2">99.1</font></td>
			<td>
				<font size="2">Press Release, dated December 13, 2012.</font></td>
		</tr>

</table>
</font>
	</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>newsrelease.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>XOMA Appoints Joseph M. Limber to Its Board of Directors</title></head><body><p align="right">EXHIBIT 99.1</p><h3 align="center">XOMA Appoints Joseph M. Limber to Its Board of Directors</h3><p>BERKELEY, Calif., Dec. 13, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that Joseph M. Limber has been appointed to its Board of Directors. Mr. Limber brings over 30 years of unparalleled biotechnology and corporate leadership experience to XOMA's Board, including from his current position as President and Chief Executive Officer of Prometheus Laboratories, a Nestl&#233; Health Science company.</p><p>
	"I am pleased to welcome Joe to our Board of Directors," stated John Varian, Chief Executive Officer of XOMA.&#160;"Our team is particularly excited to work closely with Joe, as he has successfully developed markets for specialty pharmaceutical products and managed the critical transition from research organization to commercial entity.&#160;We expect to make the same transition in the coming years and Joe's insight and guidance while we prepare for a gevokizumab commercial launch will be instrumental to our future success."</p><p>
	Mr. Limber led a significant expansion of Prometheus Laboratories' business, both organically through internally developed products and through product acquisitions.&#160;He led negotiations to acquire exclusive U.S. commercial rights to ENTOCORT EC from AstraZeneca and Proleukin from Novartis, as well as the purchase of Lotronex from GlaxoSmithKline.&#160;Mr. Limber's leadership helped Prometheus Laboratories grow its revenues to over $500 million, representing an approximate 30% CAGR with a 30% operating margin. &#160;</p><p>
	Prior to joining Prometheus in 2003, Mr. Limber was a consultant and interim Chief Executive Officer of Deltagen, Inc., a provider of drug discovery tools and services to the biopharmaceutical industry.&#160;From April 1998 to December 2002, Mr. Limber was President and Chief Executive Officer of ACLARA BioSciences, Inc., a developer of assay technologies and lab-on-a-chip systems for life science research.&#160;From 1996 to 1998, he was the President and Chief Operating Officer of Praecis Pharmaceuticals, a biotechnology company focused on the discovery and development of pharmaceutical products.&#160;Prior to Praecis, Mr. Limber served as Executive Vice President of SEQUUS Pharmaceuticals, Inc.&#160;He also held management positions in marketing and sales with Syntex Corporation and with Ciba-Geigy Corporation. Prometheus Laboratories was acquired by Nestl&#233; Health Science in July of 2011. &#160;Mr. Limber has held seats on the Boards of Directors at numerous companies, including Panacos Pharmaceuticals, Molecular Insight Pharmaceuticals and CombiMatrix Corporation.</p><p>
	<strong>About XOMA </strong></p><p>
	XOMA combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations.&#160; XOMA focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases.&#160;XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Les Laboratoires Servier (Servier) through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases.&#160;XOMA's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major effect on the treatment of diabetes.&#160;In order to retain significant value from its scientific discoveries, XOMA initiated commercial operations in January 2012 through the licensing of U.S. commercial rights to Servier's ACEON (perindopril erbumine) and a patent-protected portfolio of product candidates.&#160;</p><p>
	More detailed information can be found at www.xoma.com.&#160;</p><p>
	The XOMA&#160;Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5960</p><p>
	<strong>Forward-Looking Statements&#160;</strong></p><p>
	Certain statements contained in this press release including, but not limited to, statements related to XOMA's anticipated transition to a commercial organization upon receipt of commercial marketing approval for gevokizumab, or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.&#160;These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market.&#160;Potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings.&#160;Consider such risks carefully when considering XOMA's prospects.&#160;Any forward-looking statement in this press release represents XOMA's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.</p><pre>CONTACT: XOMA Corporation

         Company and Investor Contact:
         Ashleigh Barreto
         510-204-7482
         barreto@xoma.com

         Juliane Snowden
         The Oratorium Group, LLC
         jsnowden@oratoriumgroup.com

         Media Contact:
         Canale Communications
         Carolyn Hawley
         619-849-5375
         carolyn@canalecomm.com</pre></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
